2009 – 91st Annual Meeting

[tabs style=”default” title=”2009″] [tab title=”Saturday, Apr.25″]


Contouring Learning Lab: Contouring for GI, Lung and Prostate Cancer


[/tab] [tab title=”Sunday, Apr.26″]


  • Bruce G. Haffty, MD; UMDNJ–Robert Wood Johnson Medical School
    Molecular and Genetic Factors in Local-Regional Management of Breast Cancer: Lessons Learned


Moderator: Meena S. Moran, MD; Yale University School of Medicine

  • (S001) A Comparison of Axillary Failure Rates Following Sentinel Lymph Node Dissection Alone Versus Sentinel Lymph Node Dissection Followed by Axillary Dissection in Patients With Early Stage Breast Cancer Treated With Tangential Breast Irradiation
    A. Gabriella Wernicke, MD
  • (S002) Impact of Nodal Irradiation and Fraction Size on Cardiac and Cerebrovascular Mortality in Localized and Locoregional Breast Cancers Erika Stokes, MD
  • (S003) The Impact of Margin Status on the Local Control of Breast Conserving Patients: Does Adjuvant Therapy Play a Role? Sabin B. Motwani, MD
  • (S004) Outcomes of Node-Negative Breast Cancer 5 cm and Larger Treated With and Without Postmastectomy Radiotherapy Jennifer M. Goulart
  • (S005) Interstitial High Dose Rate (HDR) Brachytherapy for Early Stage Breast Cancer: Median 5 Year Follow-up 190 Cases Using Multi-Catheter Technique Rufus J. Mark, MD
  • (S006) Prone Whole Breast Irradiation Using 3D Conformal Radiotherapy in Women Undergoing Breast Conservation for Early Disease Yields High Rates of Excellent-Good Cosmetic Outcomes in Large-Pendulous Breasts Carmen Bergom, MD
  • (S007) Clinical-Pathologic Features of Tubular Carcinoma of the Breast Treated With Breast Conservation Therapy: The Yale University Experience Gene-Fu F. Liu, BA – TRAVEL GRANT WINNER
  • (S008) Long-Term Outcomes in Women With Early Stage Breast Cancer as a Function of Age Rahul R. Parikh—TRAVEL GRANT WINNER
  • (S009) Locoregional Recurrence in Young Women With Node-Negative Breast Cancer Treated With Mastectomy, Axillary Lymph Node Evaluation and Adjuvant Chemotherapy
    Beth M. Beadle, MD


Moderators: Sung Kim, MD; Cancer Institute of New Jersey
Alan Pollack, MD, PhD; University of Miami

  • (S010) Towards Individualized Nodal Target Volumes in High-Risk Prostate Cancer Patients Using SPECT Lymphoscintigraphy D.J. Ma, MD – TRAVEL GRANT WINNER
  • (S011) Intermediate Risk Prostate Cancer; Outcomes Related to Radiation Dose and the Use of Hormone Therapy Michelle S. Ludwig, MD
  • (S012) Validating the Partin Tables Using the NCI SEER Database James B. Yu, MD
  • (S013) Urinary Incontinence After Image Guided Radiation Therapy for Prostate Cancer
    E. Obedian, MD
  • (S014) Biochemical Control and Nadir Following Permanent Prostate Seed Implant (PPI) Brachytherapy, High-Dose Three Dimensional Conformal Radiotherapy (3DCRT), and High- Dose Conformal Proton Beam Radiotherapy (CPBRT) Boost Siavash Jabbari, MD
  • (S015) A Comparative Toxicity Analysis of Pelvic Lymph Node Versus Prostate Bed Only Radiotherapy Following Radical Prostatectomy in Prostate Cancer Patients
    Mariam P. Korah, MD
  • (S016) Image-Guided Radiotherapy for Prostate Bed Localization: Analysis of Movement
    Ron Allison, MD
  • (S017) A New Targeting Strategy for Metastatic Prostate Cancer (CaP) Utilizing a Prostate-Specific Membrane Antigen (PSMA)-Binding Pentanedioic Acid (DUPA) Song-Chu Ko, MD


Panel Chair: Mohan Suntha, MD; University of Maryland
Jaffer Ajani, MD; M.D. Anderson Cancer Center
Mark Krasna, MD; St. Joseph Medical Center

[/tab] [tab title=”Monday, Apr.27″]

Beth Erickson, MD; Medical College of Wisconsin


Paul Harari, MD; University of Wisconsin
Molecular Targeting and Radiation Oncology: New Opportunities


Moderators: Jonathan J. Beitler, MD, MBA, FACR; The Emory Clinic
Quynh-Thu Le, MD; Stanford University

  • (S018) Comparable Outcomes Following Definitive Sequential Versus Concurrent Chemoradiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck P.E. Schaner, MD
  • (S019) Arytenoid, Cricoid and Thyroid Sclerosis and CT Imaging as Predictor for Extralaryngeal Disease Jonathan J. Beitler, MD, MBA
  • (S020) Clinicopathological Risk Factors Predicting Contralateral Nodal Involvement and Survival in Squamous Cell Carcinoma of the Mobile Tongue Shane Lloyd, BA
  • (S021) Clinical Outcomes for T1-2 N0 Oral Tongue Carcinoma Treated With Surgery Without Adjuvant Radiation Therapy Ashley W. Jensen, MD
  • (S022) Integration of Cetuximab Into a Concurrent Chemoradiation Regimen for Locally Advanced Head and Neck Cancer: Preliminary Results From a Phase II Trial
    Johnny Kao, M.D.
  • (S023) Capecitabine (CAP) and Mitomycin-C (MMC) Used Concurrently With Accelerated Concomitant Boost Radiation Therapy (CB-RT) in Head and Neck Cancer (SCCHN): A Prospective Phase I/II Clinical Trial Roy H. Decker, MD, PhD
  • (S024) Definitive Concurrent Chemoradiotherapy (CRT) for Loco-Regionally Advanced Head/Neck Cancers (HNC): A Comparative Analysis of Weekly Low-Dose (Qwk) Versus Every 3-Week Full-Dose (Q3wk) Platinum Regimens in 136 Patients A. Jason Zauls, MD
  • (S025) Outcomes for T4 Squamous Cell Carcinoma of the Head and Neck Managed With Definitive Radiotherapy and Concurrent Systemic Chemotherapy Marcus M. Wagner, MD
  • (S026) Weekly Cisplatin in Combination With IMRT for Head and Neck Malignancies: The University of Wisconsin Experience Gregory M. Richards, MD—TRAVEL GRANT WINNER


Moderators: Laurie E. Gaspar, MD, MBA; University of Colorado
Roy H. Decker, MD, PhD; Yale University School of Medicine

  • (S027) Reverse Phase Protein Arrays Reveal Biomarkers of Radiation Resistance in Head and Neck and Lung Cancer Cell Lines John S. Yordy, MD – TRAVEL GRANT WINNER
  • (S028) Stereotactic Body Radiotherapy (SBRT) for Stage I Non-Small Cell Lung Cancer (NSCLC): The Memorial Sloan- Kettering Cancer Center (MSKCC) Experience
    Vishal Gupta, MD
  • (S029) Association Between Heterozygous Ct Genotype of TGF-beta 1 Gene At rs1982073:T869C and the Outcomes of Patients With Non-Small Cell Lung Cancer Treated With Definitive Radiotherapy Xianglin Yuan, MD
  • (S030) A Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC) Ritsuko Komaki, MD
  • (S031) Pleural Intensity Modulated Radiation Therapy in Patients With Malignant Pleural Mesothelioma Kenneth E. Rosenzweig, MD
  • (S032) Radiation Therapy Increases Survival in Surgically Treated Localized Invasive Thymomas and Thymic Carcinomas: An Analysis of the SEER Database
    Joshua E. Meyer, MD – TRAVEL GRANT WINNER
  • (S033) Postoperative Radiotherapy After Surgical Resection of Thymoma: Differing Roles in Localized (LOC) and Regional (REG) Disease Jeffrey A. Forquer, MD
  • (S034) Protons Safely Allow Coverage of High Risk Nodes for Patients With Regionally Advanced NSCLC R.C. Nichols, MD


Panel Chair: Kaled Alektiar, MD; Memorial Sloan-Kettering Cancer Center
Samuel Singer, MD; Memorial Sloan-Kettering Cancer Center

[/tab] [tab title=”Tuesday, Apr.28″]


Larry Kun, MD; St. Jude Children’s Research Hospital
Radiation Therapy—A Central Role in Pediatric Cancer


Moderators: Howard Colman, MD; UT M.D. Anderson Cancer Center
Vani Vijayakumar, MD; University of Mississippi

  • (S035) An Optimized Multigene Predictor for Personalization of Therapy in Glioblastoma Howard Colman, MD
  • (S036) Impact of Intraoperative High-Field Magnetic Resonance Imaging on Volumetric Extent of Resection in Glioma Patients Raymond Sawaya, MD
  • (S037) Stereotactic Radiotherapy for Juxtapapillary Choroidal Melanoma: 3 Year Follow-Up Arjun Sahgal, MD
  • (S038) Is FDG-PET a Valuable Tool to Work Out the Indication for Radiotherapy in Advanced Stage Hodgkin’s Lymphoma?—Results of the GHSG Trial HD-15 Rolf-P. Mueller, MD
  • (S039) A Comparison of Second Malignancy Risk Following Pediatric Hodgkins Lymphoma In Two Eras, 1973-1984 Versus 1986-2005: A SEER Analysis Kenneth B. Roberts, MD
  • (S040) Impact of PET-CT in Radiotherapy Field Delineation for Pediatric Hodgkin Lymphoma Arnold C. Paulino, MD
  • (S041) The Impact of Radiation Therapy on Soft Tissue Sarcomas of the Extremity: A SEER Analysis Matthew Koshy, MD

DEBATE: WBRT Versus No WBRT Following SRS for Brain Metastasis
Eric Chang, MD; M.D. Anderson Cancer Center
Roy Patchell, MD; Barrow Neurological Institute


Moderators: Christopher H. Crane, MD; UT M.D. Anderson Cancer Center
Andre A. Konski, MD, MBA, MA, FACR; Fox Chase Cancer Center

  • (S042) Radiotherapy Increases Cardiac Events in Esophageal Cancer Patients: Outcomes From the SEER-Medicare Cohort With Implications for Improvement of Tumor Targeting and Role of Post-Treatment Pharmacomodulation Mary Frances McAleer, MD, PhD
  • (S043) PET SUV for Primary Tumor Predicts for Outcomes in Locally Advanced Esophageal Cancer Treated With Trimodality Therapy Gregory M. Videtic, MD
  • (S044) Multimodality Therapy for Locoregional Extrahepatic Cholangiocarcinoma: A Population-Based Parametric Survival Analysis MeHee Choi, MD – TRAVEL GRANT WINNER
  • (S045) Liver Tumor Motion Compensation During Real Time Respiratory Tracking Using Gold Fiducial Markers Kim Huang, MD
  • (S046) Normal Tissue Complication Probability (NTCP) Modeling of Cardiac Toxicity in Patients With Esophageal Cancer Undergoing Chemoradiation Andre A. Konski, MD, MBA, MA
  • (S047) Treatment of Anal Carcinoma in Immuno-compromised Patient Populations
    R.B. Barriger, MD


Panel Chair: David Wazer, MD; Tufts Medical Center
Gail Lebovic, MD; The Cooper Clinic at Craig Ranch

Ivo Olivotto, MD; British Columbia Cancer Agency

[/tab] [tab title=”Wednesday, Apr.29″]


Joachim Yahalom, MD; Memorial Sloan-Kettering Cancer Center
David J. Stewart, MD; M.D. Anderson Cancer Center Radiation Sensitization by Systemic Therapies Cisplatin and Beyond


Moderator: David K. Gaffney, PhD, MD; University of Utah

  • (S048) Impact of Chemoradiotherapy on Survival in Primary Vaginal Cancer
    Victor J. Gonzalez, MD
  • (S049) Is There a Dosimetric Correlate for Hematological Toxicity in Cervical Cancer Patients Treated With Concurrent Chemotherapy and Extended-Field Intensity-Modulated Pelvic Radiotherapy (EF-IMRT)? Gregory N. Gan, PhD
  • (S050) Interaction of Two Radiosensitizers Cisplatin and Triapine (NSC #663249) in Cervical Cancer Charles Kunos, MD
  • (S051) F-18 Fluorodeoxyglucose Uptake in Primary Cervical Cancer and Regional Lymph Nodes Predicts Prognosis After Radiation Therapy Wenqing Sun, MD
  • (S052) A Population-Based Study of Subsequent Primary Malignancies Associated With Endometrial Cancer: Genetic, Environmental and Treatment-Related Associations
    David K. Gaffney, MD
  • (S053) Outcomes of Patients With Stage IB Cervical Carcinoma Managed With Surgery Alone vs. Surgery Plus Postoperative Radiation Therapy M. Monaghan, MD
  • (S054) Expression of Carbonic Anhydrase XII in Cervical Cancer Is Associated With Differentiation Status and Superior Radiotherapy Outcome Joo-Young Kim, MD
  • (S055) Clinicopathological Significance of Excision Repair Cross-Complementation 1 (ERCC1) Expression in Patients Treated With Breast Conserving Surgery and Radiation Therapy
    Sharad Goyal, MD
  • (S056) Clinical Efficacy of Electroacupuncture Therapy for Radiation-Induced Xerostomia
  • (S057) Decreased Cancer Survival in Individuals Separated at Time of Diagnosis
    P.A. Johnstone, MD


Panel Chair: Steve Hahn, MD – Introduction; University of Pennsylvania School of Medicine
James Metz, MD; University of Pennsylvania School of Medicine
Indra Das, PhD; University of Indiana
Justin Bekelman, MD; University of Pennsylvania School of Medicine


Moderators: Bruce G. Haffty, MD, ARS President; UMDNJ–Robert Wood Johnson Medical School
Raymond Sawaya, MD; ARS President-Elect; MD Anderson Cancer Center

  • (S058) Analysis of Clinical and Dosimetric Factors Associated With Change in Renal Function in Patients With Gastrointestinal Malignancies Following Chemoradiation to the Abdomen Kilian Salerno May, MD
  • (S059) Comprehensive Analysis of Pulmonary Function Test (PFT) Changes After Stereotactic Body Radiotherapy (SBRT) for Stage I Lung Cancer in Medically Inoperable Patients
    Kevin L. Stephans, MD
  • (S060) A Low Initial Specific Uptake Value on FDG-PET Scan May Predict for Decreased Local Control in Patients Treated With Image Guided Stereotactic Body Radiotherapy (IGSBRT) for Lung Cancer Navesh K. Sharma, DO
  • (S061) No Evidence of Racial Survival Disparities When Head and Neck Cancer Patients Receive Similar Multidisciplinary Directed Cancer Care: Results of a Matched Pair Analysis Leon M. Chen, BS
  • (S062) Effects of Riluzole and Ionizing Radiation in Metabotropic Glutamate Receptor1 (GRM1) Positive Human Melanoma C. Green, BS
  • (S063) A Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients With Advanced Solid Malignancies Thomas J. Pugh, MD
  • (S064) Tubular Carcinoma of the Breast Compared with Invasive Ductal Carcinoma Treated with Breast Conservation Therapy Gene-Fu F Liu, MSIV
[/tab] [/tabs]